Oral roxadustat three times weekly in ESA‐naïve and ESA‐converted patients with anemia of chronic kidney disease on hemodialysis: Results from two phase 3 studies

Roxadustat is a hypoxia‐inducible factor prolyl hydroxylase inhibitor approved in China for anemia of dialysis‐dependent chronic kidney disease (CKD). Japanese hemodialysis patients with anemia of CKD previously naïve to, or converted from, erythropoiesis‐stimulating agents (ESAs) were enrolled in t...

Descripción completa

Detalles Bibliográficos
Autores principales: Akizawa, Tadao, Ueno, Mai, Shiga, Takanori, Reusch, Michael
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley & Sons Australia, Ltd 2020
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7687179/
https://www.ncbi.nlm.nih.gov/pubmed/31891449
http://dx.doi.org/10.1111/1744-9987.13468

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7687179/
https://www.ncbi.nlm.nih.gov/pubmed/31891449
http://dx.doi.org/10.1111/1744-9987.13468

Ejemplares similares